These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 3759440)

  • 1. Effect of desferrioxamine on salivary iron in thalassemic children.
    Greif Z; Heno N; Said N; Freundlich E
    Isr J Med Sci; 1986 Jun; 22(6):482-3. PubMed ID: 3759440
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes in urinary iron in thalassemia major in relation to the administration of desferrioxamine].
    Esposito L; Ferrara M; Galdo Capotorti M
    Pediatria (Napoli); 1978 Mar; 86(1):69-76. PubMed ID: 683795
    [No Abstract]   [Full Text] [Related]  

  • 3. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 4. Iron status in thalassemia major patients after long-term subcutaneous desferrioxamine.
    Kontopoulou-Griva I; Hatzidimitriou-Papazacharia K; Spiliotopoulou J; Tsagarakis N; Digenopoulou E
    Birth Defects Orig Artic Ser; 1988; 23(5B):111-6. PubMed ID: 3390532
    [No Abstract]   [Full Text] [Related]  

  • 5. Desferrioxamine-induced iron outputs in Cooley's anemia. Results and perspectives.
    Cantore N; Tortarolo M; Volpe E; Gonnella F; Valente A; Buonanno G
    Haematologica; 1981 Apr; 66(2):196-207. PubMed ID: 6791996
    [No Abstract]   [Full Text] [Related]  

  • 6. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of desferrioxamine on iron elimination in children after multiple transfusions].
    Leggio ML
    Minerva Pediatr; 1966 Feb; 18(3):101-3. PubMed ID: 5930397
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early iron chelation therapy in thalassemia major.
    Russo G; Romeo MA; Musumeci S; Schilirò G; Di Gregorio F
    Haematologica; 1983; 68(1):69-73. PubMed ID: 6404710
    [No Abstract]   [Full Text] [Related]  

  • 12. [Thalassemia major: chelating therapy with deferoxamine].
    Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
    Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathogenesis and management of iron overload in thalassemia.
    Hershko C
    Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456
    [No Abstract]   [Full Text] [Related]  

  • 14. [Research on the effect of desferrioxamine B in patients with Cooley's disease].
    Silvestroni E; Bianco I; Masi M
    Policlinico Prat; 1967 Dec; 74(50):1681-90. PubMed ID: 4240868
    [No Abstract]   [Full Text] [Related]  

  • 15. Subcutaneous diethylene triamine pentaacetic acid: comparison with desferrioxamine in thalassemic patients with iron overload.
    Pippard MJ; Jackson MJ; Modell CB
    Birth Defects Orig Artic Ser; 1988; 23(5B):105-9. PubMed ID: 3390531
    [No Abstract]   [Full Text] [Related]  

  • 16. Iron balance and the management of iron overload in beta-thalassemia intermedia.
    Pippard MJ; Weatherall DJ
    Birth Defects Orig Artic Ser; 1988; 23(5B):29-33. PubMed ID: 3390555
    [No Abstract]   [Full Text] [Related]  

  • 17. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients.
    Piomelli S; Graziano J; Karpatkin M; Dudell GG; Hart D; Hilgartner M; Khanna K; Valdes-Cruz LM; Vora S
    Ann N Y Acad Sci; 1980; 344():409-17. PubMed ID: 6930881
    [No Abstract]   [Full Text] [Related]  

  • 18. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 19. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
    Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
    Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
    [No Abstract]   [Full Text] [Related]  

  • 20. [Desferrioxamine B treatment of 4 splenectomized cases of Cooley's anemia].
    Rossi R; Frangini V; Pratesi C
    Riv Clin Pediatr; 1968; 81(5):1002-9. PubMed ID: 5740180
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.